Clinical Trial Update: Apatinib in Refractory Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for apatinib in refractory colorectal cancer (colorectal neoplasms) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Neoplasms

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED